MRLV
Overview
MRL Ventures Fund (MRLV) is the therapeutics-focused corporate venture fund of Merck & Co., Inc. From its headquarters in Cambridge, Mass., USA, the MRLV team invests globally in early-stage innovative therapeutics companies that are developing transformative medicines in any therapeutics area using any modality . The fund does not invest in medical devices, diagnostic platforms or digital health .
Investments
| Company | Date | Stage | Lead |
|---|---|---|---|
| Therini Bio | May 2025 | Series A Extension | Co-investor |
| PAQ | May 2025 | Series B | Lead |
| AXONIS Therapeutics | Oct 2024 | Series A | Co-investor |
| Aktis Oncology | Sep 2024 | Series B | Co-investor |
| InduPro | Jun 2024 | Series A | Co-investor |
Sector & Stage Mix
Industry, funding stage, and valuation band breakdowns.